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Abstract
Background: Few data are available on the prevalence of erosive and severe esophagitis in Western countries.
Objective: To retrospectively determine the prevalence and the factors predicting erosive esophagitis and severe
esophagitis in a large series of endoscopies in Spain.
Design: Retrospective observational study. A multivariate analysis was performed to determine variables predicting severe
esophagitis.
Setting: Databases of 29 Spanish endoscopy units.
Patients: Patients submitted to a diagnostic endoscopy during the year 2005.
Interventions: Retrospective review of the databases.
Main Outcome Measurements: Esophagitis severity (graded according to the Los Angeles classification) and associated
endoscopic findings.
Results: Esophagitis was observed in 8.7% of the 93,699 endoscopies reviewed. Severe esophagitis (LA grade C or D)
accounted for 22.5% of cases of the disease and was found in 1.9% of all endoscopies. Incidences of esophagitis and those
of severe esophagitis were 86.2 and 18.7 cases per 100,000 inhabitants per year respectively. Male sex (OR 1.89) and
advanced age (OR 4.2 for patients in the fourth age quartile) were the only variables associated with severe esophagitis.
Associated peptic ulcer was present in 8.8% of cases.
Limitations: Retrospective study, no data on individual proton pump inhibitors use.
Conclusions: Severe esophagitis is an infrequent finding in Spain. It occurs predominantly in males and in older individuals.
Peptic ulcer disease is frequently associated with erosive esophagitis.
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Introduction
Prevalence of symptoms of gastro-esophageal reflux disease
(GERD) is uniformly high in Western countries. Studies on GERD
prevalence show that between 10% and 20% of the Western
general population report GERD symptoms (reflux, regurgitation
or both) at least once a week [1–5]. Studies performed in Spain
showed similar prevalences of frequent GERD symptoms ranging
from 9.8% [6] to 12% [7]. Although little information is available,
two longitudinal series estimated that the yearly incidence of newly
diagnosed GERD ranges from 4.5% to 5.4% [8,9]. Much less is
known about the frequency of endoscopic lesions and, specifically,
of severe esophagitis. Studies suggest that when endoscopy is
performed to study reflux symptoms erosive esophagitis is found in
approximately 50% of patients [10–14]. Similarly, in a recent US
study approximately 60% of volunteers with frequent heartburn
participating in a clinical trial had esophagitis. In that study,
prevalence of severe disease was unexpectedly high: 29.6% of
patients had grade A or B and 25.8% grade C or D esophagitis
[15] on the Los Angeles classification [16]. By contrast, studies in
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the general population suggest a yearly incidence of erosive
esophagitis of 15 to 25 per 1000 persons/year, approximately ten
times lower than that of occasional GERD symptoms [17,18].
In addition, management of acid-related diseases has been
modified by the widespread availability of proton pump inhibitors
(PPI) both as prescription and over-the-counter drugs. Empirical
treatment of heartburn before endoscopy is currently the rule and
it is well known that the prevalence of endoscopic findings is
sharply reduced by previous antisecretory treatment [19]. It would
be interesting to determine whether the diagnosis of severe
esophagitis remains frequent under the current conditions of
widespread PPI use.
Finally, to our knowledge, there are no published studies
estimating the prevalence of erosive esophagitis in the Mediter-
ranean area. For all these reasons, the present study was designed
to retrospectively assess the current prevalence of peptic
esophagitis, and especially of forms of severe disease, from the
records of a large sample of Gastrointestinal Endoscopy Units in
Spain.
Methods
Ethics Statement
The study was reviewed and approved by the Ethics
Committees of both the Hospital Universitari La Fe and the
Hospital de Sabadell. A written informed consent was obtained
from all participants involved in the study. Data were coded in
order to avoid patient identification.
Study Design
Thirty-five Gastrointestinal Endoscopy Units were invited to
participate in the study, and twenty-nine accepted (figure 1). The
main reason for declining participation in the study was the lack of
an electronic database allowing easy data retrieval. General
information was provided on the endoscopy unit, including the
number of upper gastrointestinal endoscopies performed in 2005
and the rate of endoscopies ordered by general practitioners. In
addition, the hospital level and the population served were
obtained from the Annual Administrative Reports of the
participating hospitals for 2005. Data from the upper endoscopies
performed from January to December 2005 were retrieved from
the databases of the different units. The number and demographic
characteristics (age and gender) of patients with endoscopic
diagnosis of peptic esophagitis, the severity of the disease – graded
according to the Los Angeles (LA) classification system [16] – and
the associated endoscopic findings were specifically recorded.
Severe esophagitis was defined as LA grade C or D lesions. Data
were recorded in two MS Excel databases – one for the hospital
and general data, and the other for information on the individual
patient.
Demographic data for the reference populations of the different
hospitals for 2005 were retrieved from Spanish government
databases [20]. Finally, in an attempt to determine indirectly
whether the use of antisecretory drugs could influence the rates of
the endoscopic diagnosis of esophagitis, data on the regional sales
of these drugs were compared with the rates of esophageal disease
in the area. Data on drug sales were kindly provided by IMS
Health S.A. (2005 antisecretory drugs sales in Spain, IMS Health
S.A:. Madrid-Spain).
Statistical analysis
The prevalence of peptic esophagitis and severe esophagitis
were calculated for the total number of endoscopies. In addition,
age was divided into ten-year intervals and the prevalence of
esophagitis and severe esophagitis was determined for each age
interval. Yearly incidence of esophagitis was also calculated.
Mann-Whitney U test was used for comparing quantitative
variables to the occurrence of esophagitis and severe esophagitis.
Additionally, a multiple logistic regression model was performed to
identify factors associated with the occurrence of esophagitis. SPSS
11 was used for the analyses.
Sample size calculation
The study was designed to evaluate the prevalence of severe
esophagitis with a confidence interval of 61%. Extrapolating from
the literature, we assumed that 25% of all esophagitis would be
severe and that esophagitis would be found in 40% of all
endoscopies. The estimated minimal number of endoscopies to
analyze was 5972.
Results
Number of endoscopies and referral population
The 29 participating hospitals were widely distributed through-
out Spain (figure 1). They provided medical assistance for a total
population of 10,431,252 individuals, corresponding to 23.6% of
the entire Spanish population. The mean referral population was
324,536 subjects per hospital, ranging from 107,000 to 787,000
subjects. Twenty-two institutions were high-level teaching hospi-
tals and 7 were county hospitals. 93,699 upper endoscopies were
performed during 2005, a rate of 0.89 endoscopies per 100
habitants per year.
Number of patients with esophagitis and severe
esophagitis
Esophagitis was reported in 8,189 endoscopies (8.7% of all those
performed during 2005). Esophagitis patients’ age ranged from 15
to 105 years (mean 53.5618 years). Sex distribution was: 5649
male and 2540 female. According to the LA classification [16],
esophagitis severity was graded as A in 3754 patients (45.8%), B in
2595 (31.7%), C in 960 (11.7%) and D in 880 (10.8%) (table 1).
Severe peptic esophagitis (LA C–D) was, therefore, detected in
22.5% of patients, representing 1.9% of all endoscopies.
Peptic esophagitis was more prevalent in males (69%). Severe
esophagitis was also mainly diagnosed in males and its prevalence
increased at advanced age; nearly 40% of the esophagitis in
patients over 70 years were LA C and D (figure 2).
Figure 1. Geographical distribution of participating centres.
doi:10.1371/journal.pone.0025051.g001
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Annual incidence of endoscopic esophagitis was 86.2 cases per
100,000 habitants per year. Incidence of severe esophagitis (LA
grade C or D) was 18.7 cases per 100,000 habitants per year.
A logistic regression was performed to ascertain the risk increase
for severe esophagitis associated with increasing age and male sex.
Both variables were found to be independently related to the
development of severe esophagitis, with the risk increasing
geometrically with age with an OR of 4.2 in the patients in the
fourth quartile. OR was 1.89 for males (table 2). Regression was
validated using the ROC curve method. Area under the curve was
0.663 with a p value lower than 0.001.
Associated endoscopic findings
Esophagitis associated to esophageal or gastric malignancy was
unusual: 27 (0.3%) and 74 (0.9%) endoscopies respectively. By
contrast, gastro-duodenal peptic disease was very frequently
associated with reflux esophagitis. Thus, duodenal ulcer was
present in 5.6% of endoscopies, gastric ulcer in 3% and combined
gastric and duodenal ulcers in 0.2%.Erosive duodenitis was
present in 9.6% and gastric erosions in 7.7% of patients with
esophagitis. Overall, 8.8% of patients had a peptic ulcer and
22.4% of patients had some kind of peptic lesion, many having
more than one type of lesion. Both peptic ulcer (10% vs. 5.8%) and
peptic lesions (24.6% vs. 18.8%) were significantly more frequent
in males. In addition, prevalence of both duodenal and gastric
ulcer increased with age, from 3.4% and 0.8% in patients in their
twenties to 7.4% and 5.3% in patients over 80 years respectively.
By contrast, erosive gastritis and duodenitis remained more stable,
increasing only from 5.3% to 7.4% and from 5.1% to 7.9%
respectively.
Risk factors related to severe esophagitis
Prevalence of severe esophagitis was not related to hospital level
(15.6 cases per 100,000 habitants for county hospitals vs. 14.8
cases for 100,000 habitants for reference hospitals), or to the rate
of endoscopies indicated by general practitioners, the number of
inhabitants in the reference area, the mean age of the population
or the regional expenditure on PPI.
Discussion
Our study suggests that, in Spain, peptic esophagitis is unusual
(8.7%) in patients who undergo upper endoscopy for a variety of
upper gastrointestinal symptoms. Severe esophagitis is even less
frequent, appearing in fewer than 2% of endoscopies. Moreover,
the figure of 18 cases per 100,000 patients-years yearly incidence
of severe esophagitis is one of the first estimates of the incidence of
this disease in a Mediterranean country.
In addition, our study confirms the results of published studies
suggesting that advanced age [21–25] and male sex
[11,17,23,25,26] are important risk factors for severe erosive
esophagitis. The combination of male sex and advanced age
produces an almost tenfold increase in the risk of severe
esophagitis. There is no complete explanation for these findings.
In the case of age, it is reasonable to hypothesize that the age-
related decrease in esophageal sensitivity could allow more severe
lesions to develop before medical advice is sought. This hypothesis
is in concordance with other studies in which elderly subjects had a
significantly lower prevalence [21] and severity [22] of typical
gastroesphageal reflux symptoms. However, not all data, support
this hypothesis. In a study reported only in abstract form, Fennerty
et al [15] observed that the prevalence of severe esophagitis was
higher in young patients (age ,65 years). The data from this last
study should, however, be considered with care since the subjects
recruited were volunteers participating in a clinical trial, with the
result that the risk of selection bias was high.
Another interesting finding of our study is that the prevalence of
associated peptic ulcer disease in patients with an unequivocal
diagnosis of GERD was almost 10% and that peptic erosions were
found in more than 20% of the endoscopies. As countries in the
Mediterranean area like Spain have a high prevalence of Helicobacter
pylori infection [27] and both peptic ulcer and esophagitis are
frequent diseases, the association of the two conditions is also
expected to be frequent. The finding of a very high prevalence of
gastroduodenal ulcer in patients with typical reflux symptoms or
esophagitis has also been observed in other areas where Helicobacter
pylori infection is highly prevalent, for example in Asia [25,28,29].
Taken together these data suggest that, in areas with a high
Table 1. Severity of esophagitis according to sex.
LA classification Total
A B C D
SEX Male n 2326 1917 738 668 5649
% 41.2 33.9 13.1 11.8 100
female n 1428 678 222 212 2540
% 56.2 26.7 8.7 8.4 100
Total n 3754 2595 960 880 8189
% 45.8 31.7 11.7 10.8 100
doi:10.1371/journal.pone.0025051.t001
Figure 2. Severity of esophagitis according to age.
doi:10.1371/journal.pone.0025051.g002
Table 2. Results of the multivariate analysis.
Sig. Exp(B) 95% C.I.for EXP(B)
Age (quartiles) Lower Upper
14–39 ,000 1
40–52 ,000 1.408 1.176 1.686
53–68 ,000 2.018 1.701 2.394
69–105 ,000 4.223 3.584 4.977
Male sex ,000 1.889 1.660 2.148
doi:10.1371/journal.pone.0025051.t002
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prevalence of Helicobacter pylori infection, empirical PPI treatment for
suspected GERD may be inadequate for a significant proportion of
patients since Helicobacter pylori-related peptic ulcer disease is often an
associated finding. In consequence, Helicobacter pylori should
probably be investigated and treated to rule out peptic disease
before assigning the patient to chronic PPI therapy for clinically – or
even endoscopically – diagnosed GERD.
A major strength of the study is that the total referral population
- over 10 million individuals - represents nearly a quarter of the
Spanish population. In addition, data were obtained from 29
hospitals from all over the country (figure 1). These factors
contribute to reduce the risk of local biases and support the
reliability of the data.
This study has, however, several methodological limitations
inherent in its retrospective design. First, the criteria for diagnosing
esophagitis or establishing their severity had a variable interob-
server rate that depends on the scoring system used and the level of
experience of the endoscopist [30–32]. However, it has been
reported that agreement between observers is better in more
severe degrees of disease [33]. It is likely, therefore, that the
accuracy of the data on the prevalence of severe esophagitis was
acceptable.
A second limitation is that, although a tentative incidence of
severe esophagitis was estimated, the study is not population-based
and the data should be treated with care. Some local factors,
however, suggest that the estimate is reliable. In Spain, the health
care system has universal coverage and the proportion of private
practice is low. In fact, public coverage of endoscopy is over 90%
in most of the areas and cross-referrals between different areas for
endoscopy are unusual. In addition, the data were consistent: for
example, despite the difference in complexity, the rate of severe
esophagitis did not differ between referral and County hospitals.
A third possible limitation (one which applies to all studies
estimating esophagitis prevalence) is that selection criteria for
endoscopy will vary between different age groups as well as between
different areas. The prevalence of different gastrointestinal lesions
varies depending on the symptoms investigated. The prevalence of
esophagitis has been reported to range from 6% to 25% in dyspeptic
patients [26,34] and from 55% to 65% in patients with
gastroesophageal reflux symptoms [15,23]. Therefore, the preva-
lence will be strongly influenced by the policy for indicating
endoscopy. This could explain the high variability of reflux
esophagitis reported in different studies, ranging, for example, from
7% to 15% in the general Japanese population [11,18]. In any case,
as severe esophagitis is associated with more severe and frequent
symptoms [23], the likelihood of missing severe disease is probably
far lower for severe than for mild esophagitis.
A final limitation of the study is that it was not possible to obtain
data on antisecretory drug use previous to the endoscopy.
Antisecretory drug use is rising continuously. For example, in a
Scandinavian study, Lassen et al [35] reported an increase in the
already high use of antisecretory drugs before endoscopy (33% in 1993
and 41% in 2002). The influence of PPI use on the prevalence of
severe esophagitis is difficult to evaluate. As stated above, endoscopic
studies suggest that acid-reducing treatment before endoscopy cures
most peptic lesions and limits its usefulness for detecting esophagitis or
peptic ulcer [19]. It could therefore be inferred that the prevalence of
esophagitis and severe disease will decrease as long as PPI use
increases. However, the evidence is scarce: only the Kalixandra study
evaluates previous treatment with antisecretory drugs [18]. Even in
this case, data are difficult to extrapolate to the current situation, as the
study dates from 1998, when the use of antisecretory drugs was low. In
addition, the authors did not attempt to correlate PPI use and the
presence or absence of esophagitis.
In conclusion, our study suggests that, at present, severe
esophagitis is not a frequent finding. Severe endoscopic disease
predominates in males and the elderly. In addition, peptic ulcer
disease and erosive gastro-duodenitis are common associated
findings. This stresses the importance of ruling out peptic ulcer,
preferably by non-invasive testing followed by Helicobacter pylori
eradication before establishing long-term PPI treatment in
countries with a high prevalence of this infection. Additional
studies will be necessary to determine the influence of antisecretory
drug treatment in the prevalence of endoscopic esophagitis.
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